Pharmacokinetic fluvoxamine-clomipramine interaction with favorable therapeutic consequences in therapy-resistant depressive patient.

Détails

ID Serval
serval:BIB_41FCDBF3455A
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Etude de cas (case report): rapporte une observation et la commente brièvement.
Collection
Publications
Institution
Titre
Pharmacokinetic fluvoxamine-clomipramine interaction with favorable therapeutic consequences in therapy-resistant depressive patient.
Périodique
Pharmacopsychiatry
Auteur⸱e⸱s
Conus P., Bondolfi G., Eap C.B., Macciardi F., Baumann P.
ISSN
0176-3679 (Print)
ISSN-L
0176-3679
Statut éditorial
Publié
Date de publication
1996
Volume
29
Numéro
3
Pages
108-110
Langue
anglais
Notes
Publication types: Case Reports ; Journal ArticlePublication Status: ppublish
Résumé
We describe the case of a depressive patient who was a rapid metabolizer of CYP2D6 substrates and a heavy smoker, and who did not respond to several courses of treatment with antidepressants, as a result of unusually low drug-plasma levels. During hospitalization, he did not improve after treatment with clomipramine (150-225 mg/day during three weeks), but showed a response within four days after addition of fluvoxamine (100 mg/day). Plasma levels of clomipramine and desmethylclomipramine changed from 58 ng/ml and 87 ng/ml to 223 ng/ml and 49 ng/ml respectively one week after addition of fluvoxamine. Present knowledge of the role of cytochrome P-450 isozymes, such as CYP1A2, CYP2C19, CYP2D6, and CYP3A4, in the metabolism of psychotropic drugs as well as therapeutic drug-plasma level monitoring may thus help to determine individual treatment.
Mots-clé
Antidepressive Agents, Second-Generation/pharmacokinetics, Antidepressive Agents, Second-Generation/therapeutic use, Antidepressive Agents, Tricyclic/pharmacokinetics, Antidepressive Agents, Tricyclic/therapeutic use, Clomipramine/pharmacokinetics, Clomipramine/therapeutic use, Combined Modality Therapy, Cytochrome P-450 CYP2D6/genetics, Cytochrome P-450 CYP2D6/metabolism, Depressive Disorder/drug therapy, Depressive Disorder/metabolism, Drug Interactions, Drug Resistance, Electroconvulsive Therapy, Fluvoxamine/pharmacokinetics, Fluvoxamine/therapeutic use, Humans, Male, Middle Aged, Phenotype, Psychiatric Status Rating Scales, Smoking/metabolism
Pubmed
Web of science
Création de la notice
02/09/2011 19:53
Dernière modification de la notice
20/08/2019 14:43
Données d'usage